Literature DB >> 9039530

Candidemia in intensive care unit patients: risk factors for mortality.

A Voss1, J L le Noble, F M Verduyn Lunel, N A Foudraine, J F Meis.   

Abstract

Aim of this study was to evaluate whether risk factors which predict the development of candidemia may also predict death in ICU patients with candidemia. During an 8-year-period all ICU patients whose blood cultures yielded Candida species (n = 40) were retrospectively evaluated in a case-control fashion. The average incidence of Candida bloodstream infections was 5.5 per 10,000 patient days, ranging from 2.4 in 1990 to 7.4 in 1994. C. albicans was the most common pathogen in candidemic patients, but the proportion of non-C. albicans strains showed an increasing trend during 1989-1993, with a major shift towards non-C. albicans species in 1994. The overall mortality of patients with candidemia was 58%. Mortality was highest in the group of patients with multi-organ dysfunction syndrome, especially among those in need of hemodialysis. Risk factors for the development of candidemia, such as age, malignancy, steroid use, i.v. catheterization, and the use of broad-spectrum antibiotics were not correlated with mortality in the ICU patients studied.

Entities:  

Mesh:

Year:  1997        PMID: 9039530     DOI: 10.1007/bf02113499

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  18 in total

1.  Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients.

Authors:  W G Powderly
Journal:  AIDS       Date:  1992-06       Impact factor: 4.177

2.  Investigation of a cluster of systemic Candida albicans infections in a neonatal intensive care unit.

Authors:  W L Vaudry; A J Tierney; W M Wenman
Journal:  J Infect Dis       Date:  1988-12       Impact factor: 5.226

3.  Risk factors for hospital-acquired candidemia. A matched case-control study.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1989-10

4.  Candida glabrata, Candida krusei, non-albicans Candida spp., and other fungal organisms in a sixty-bed national cancer center in 1989-1993: no association with the use of fluconazole.

Authors:  A Kunová; J Trupl; S Spánik; L Drgona; J Sufliarsky; J Lacka; V Studená; E Hlavácová; M Studená; E Kukucková
Journal:  Chemotherapy       Date:  1995 Jan-Feb       Impact factor: 2.544

5.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors:  S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

6.  A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study.

Authors:  J R Le Gall; S Lemeshow; F Saulnier
Journal:  JAMA       Date:  1993 Dec 22-29       Impact factor: 56.272

Review 7.  Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy.

Authors:  J R Wingard
Journal:  Clin Infect Dis       Date:  1994-08       Impact factor: 9.079

Review 8.  Importance of Candida species other than C. albicans as pathogens in oncology patients.

Authors:  J R Wingard
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

9.  Candida colonization and subsequent infections in critically ill surgical patients.

Authors:  D Pittet; M Monod; P M Suter; E Frenk; R Auckenthaler
Journal:  Ann Surg       Date:  1994-12       Impact factor: 12.969

10.  Long-term survival after intensive care unit admission with sepsis.

Authors:  K C Sasse; E Nauenberg; A Long; B Anton; H J Tucker; T W Hu
Journal:  Crit Care Med       Date:  1995-06       Impact factor: 7.598

View more
  31 in total

1.  Experience with invasive Candida infections.

Authors:  H Girishkumar; A M Yousuf; J Chivate; E Geisler
Journal:  Postgrad Med J       Date:  1999-03       Impact factor: 2.401

2.  Non-albicans Candida species isolated from plastic devices.

Authors:  E Dorko; M Kmet'ová; A Marossy; F Dorko; M Molokácová
Journal:  Mycopathologia       Date:  1999-12       Impact factor: 2.574

3.  Rapid identification of Candida species by confocal Raman microspectroscopy.

Authors:  K Maquelin; L P Choo-Smith; H P Endtz; H A Bruining; G J Puppels
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  Diagnosis of candidemia by polymerase chain reaction and blood culture: prospective study in a high-risk population and identification of variables associated with development of candidemia.

Authors:  M S Moreira-Oliveira; Y Mikami; M Miyaji; T Imai; A Z Schreiber; M L Moretti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

5.  Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 6.  [Invasive candidiasis in non-neutropenic adults : Guideline-based management in the intensive care unit].

Authors:  A Glöckner; O A Cornely
Journal:  Anaesthesist       Date:  2013-12       Impact factor: 1.041

7.  Anticandidal activity of hetero-dinuclear copper(II) Mn(II) Schiff base and its potential action of the mechanism.

Authors:  Bekir Mustafa Yoğurtçu; Selami Demirci; Ayşegül Doğan; Ayla Burçin Asutay; Fikrettin Şahin
Journal:  World J Microbiol Biotechnol       Date:  2017-10-27       Impact factor: 3.312

Review 8.  Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.

Authors:  Ercole Concia; Anna Maria Azzini; Michela Conti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Photodynamic antimicrobial chemotherapy (PACT) with methylene blue increases membrane permeability in Candida albicans.

Authors:  Ligia Maria Giroldo; Monalisa Poliana Felipe; Marco Antonio de Oliveira; Egberto Munin; Leandro Procópio Alves; Maricilia Silva Costa
Journal:  Lasers Med Sci       Date:  2007-12-22       Impact factor: 3.161

10.  Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.

Authors:  Bertrand F Dupont; Olivier Lortholary; Luis Ostrosky-Zeichner; Flavie Stucker; Vijay Yeldandi
Journal:  Crit Care       Date:  2009-10-05       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.